Pharma Industry

What clinicians should keep in mind when recommending LAI medications and helping patients receive consistent treatment

More steps are needed, including insurance coverage that could help patients.

GLP-1 drugs Wegovy, Zepbound will have lower prices and be covered by Medicare.

Part three of our three-part webinar series airs Nov. 4 at 7 p.m. ET, unpacking how most favored nation pricing, import tariffs and direct-to-consumer channels could ripple through payer contracts, 340B and practice economics.

President Trump vows to slash prices for weight-loss drugs down to $150, sparking investor concerns and renewed debate over U.S. drug pricing policy.

Joint KFF/Washington Post survey finds broad bipartisan support for food regulation — and sharp divides on vaccines and trust in public health institutions.

Pfizer was at the White House late last month; AstraZeneca touts expansion in Virginia.

In part two of MJH Life Sciences’ three-part series, experts dissect President Trump’s most-favored nation executive order, warning that its use of tariffs and foreign price benchmarks could upend drug markets and test the limits of federal authority.

Ohio State researchers say the billionaire entrepreneur’s Cost Plus Drug Company exposes how insurance premiums and middlemen drive up the true cost of neurologic medications.

Savings for patients could reach 85%, and more pharmaceutical companies will have more deals to come, administration says.

Out-of-pocket costs for popular diabetes and weight-related medications nearly doubled in 2025, with nearly universal prior authorization requirements, according to new JAMA research.

Trump’s “most favored nation” drug pricing order could lower costs but raise new challenges for physicians, patients and pharma.

RFK says ‘pharmaceutical ads hooked this country on prescription drugs,’ so a crackdown is coming.

HHS Secretary Kennedy, Ag Secretary Rollins roll out action steps for national initiative on health.

Silencing one channel without building credible alternatives risks leaving patients less informed and physicians more burdened.

A three-part webinar series, starting on Sept. 10, will bring together legal, policy and industry leaders to dissect the high-stakes implications of the MFN initiative for pharma, payers and patients.

New position paper outlines scope of problem and offers policies that could help.

Study examines potential harm to market competition by pharmacy benefit managers and health insurers.

The President shared letters to pharma CEOs on Truth Social Thursday, giving them 60 days to match U.S. drug prices to the lowest rates in other wealthy nations.

Synthetic opioid sold at stores and online is ‘a recipe for a public health disaster.’

Consumer and patient protections are in two bills that have support of doctors in Congress.

Why lower-cost alternatives struggle to gain ground

New report identifies ‘misalignment’ between research spending and chronic diseases that affect millions of people.

New tariffs of up to 200% could hit medications from the European Union and beyond, raising alarms over affordability, access and supply for physicians and patients.

FDA also publishes review letters in new drug approval process.